The association of lower CD68 infiltration and higher CD80/CD163 ratio with increased overall survival within stage III CRC supports the need for further validations and reinforces the relevance of including such markers in the already established Immunoscore. The gene discussed is CD163; the disease is colorectal carcinoma.